COMMUNIQUÉS West-GlobeNewswire

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update
06/03/2026
GLEN ALLEN, Va., March 06, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and [...]
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting
06/03/2026
Shareholders approve 29th consecutive dividend increase to CHF 3.70 (+5.7%) per share for 2025, representing a 3.0% yield¹ Shareholders confirm Giovanni Caforio as Chair of the Board of Directors as well as all other [...]
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/03/2026
BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today [...]
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio
06/03/2026
Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs Transaction represents total equity value of [...]
Prenetics Authorizes $40 Million Share Repurchase Program
06/03/2026
Management and Board Have Collectively Committed Up to $42.75 Million to Prenetics Stock Backed by $164 Million in Total Adjusted Liquidity, Zero Debt IM8 Targeting $180M to $200M in 2026 Full Year Revenue, and a Clear [...]
Tangram Therapeutics annonce l’administration de la première dose à un participant dans le cadre de l’essai RESTORE-MASH de phase I/II portant sur le TGM-312, un nouveau médicament expérimental à base d’ARNi
06/03/2026
L’essai RESTORE-MASH de phase I/II évaluera la sécurité, la pharmacocinétique et la pharmacodynamique du TGM-312 chez des volontaires en bonne santé et des patients atteints de MASH Les premières données sont attendues [...]
Solid Biosciences Announces Oversubscribed $240 Million Private Placement
06/03/2026
CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that [...]
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
06/03/2026
CORAL GABLES, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing [...]
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
06/03/2026
CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced [...]
Anathapindika Spotlight Shines on Rare Disease Day (and How Detoxification Can Help)
06/03/2026
The National Observance Supports Those Managing Less-Than-Common Struggles. Anathapindika’s Supplements Can Help the Body Defend Itself. FORT LAUDERDALE, FL, March 06, 2026 (GLOBE NEWSWIRE) -- February 28th is Rare [...]
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/03/2026
DALLAS, March 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene [...]
Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering
06/03/2026
Short Term Tranche Warrants Potentially Raise $10.4 Million within 12 months of Closing SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a [...]
Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook
06/03/2026
ACTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient tests to improve patient outcomes in [...]
Artelo Biosciences Announces Reverse Stock Split
06/03/2026
Shares Expected to Begin Trading on a Split-Adjusted Basis on March 10, 2026 SOLANA BEACH, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage [...]
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
06/03/2026
- 64% overall survival observed at 12 months in ongoing Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival; On [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
06/03/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 6 March 2026 at 16.00 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
06/03/2026
Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms Gazyva/Gazyvaro has the potential to [...]
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update
06/03/2026
Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 meeting with the U.S. Food and Drug Administration On-track for VLS-01 [...]
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
06/03/2026
Extends Company Cash Runway into Mid-2028 Financing Expected to Fund Completion of Phase 2 Ovarian Cancer Trial Financing Supports Acceleration Toward Pivotal Trial and Commercialization Financing Structured as Non- [...]

Pages